Cardiovascular and soft tissue repair patches are used to repair tissue procedures such as vascular repair, soft tissues, and restoration. The growing prevalence of heart defects such as ventricular septal and atrial septal defects in medical events and sports wounds are the major factor propelling the demand for cardiovascular and soft tissue repair patches market. The rising prevalence of hernias such as inguinal hernia, congenital diaphragmatic hernias, and others are anticipated to propel the adoption of these patches globally. Restoration of inguinal hernias is one of the most generally performed general surgeries. According to The National Digestive Diseases Information Clearinghouse (NDDIC), more than one million hernia repairs are performed in the U.S. each year. Among the total hernia procedure, about 800,000 for restoration inguinal hernias, and the remaining are for other kinds of hernias. The preference for minimally invasive surgeries and an increase in the prevalence of acquired cardiovascular & soft tissue abnormalities are expected to fuel the growth of the cardiovascular & soft tissue repair patch market globally. Moreover, growing strategic mergers and acquisitions among the key players operating in the market, growing health care expenditure is likely to supplement the global market.
The Cardiovascular & Soft Tissue Repair Patch Market is a segment based on product type, application, end-user, and geography. In terms of product type, the global market is segregated into synthetic patch and biologic patch. The biologics segment is estimated to register a high share in the global cardiovascular & soft tissue repair patch market in 2019. The biologics patch segment is further segmented into the xenogeneic patch and allogeneic patch. The biologic patch is used in soft tissue repair, and speedy progress in tissue engineering and biomaterial are some of the key factors that are predictable to boost the cardiovascular & soft tissue repair patch market over the estimated timeframe. Additionally, the companies in the cardiovascular & soft tissue repair patch market are investing more in research and development activities to develop technologically advanced products such as biologic patches is expected to boost the growth of the market significantly.
Based on the application, the market is segmented into soft tissue repair and cardiovascular repair. The soft tissue repair segment is further segmented as abdominal wall reconstruction, hernia repair, thoracic wall reconstruction, dural reconstruction, and others. The cardiovascular repair segment is further segmented into vascular reconstruction and cardiac reconstruction. The soft tissue repair segment is estimated to account for the largest share in 2019 in the global market. The growing surgical procedures such as hernia repair, dural reconstruction, abdominal wall reconstruction, etc. are propelling the growth of the segment in the global market. Based on end-user, the global soft tissue repair and cardiovascular repair market is segmented into hospitals, ambulatory surgical centers, and specialty clinics.
Based on geography, the Global Cardiovascular & Soft Tissue Repair Patch Market has been segmented into North America, Asia Pacific, Latin America, Europe, and Middle East & Africa. In terms of revenue, North America is estimated to account for the largest share in the global market in 2019. The high prevalence of cardiac diseases and a large number of surgeries carried out in the U.S. are expected to boost the growth of the market significantly in the region. Moreover, the growing consumption of junk food and adopting a sedentary lifestyle are propelling cardiovascular diseases in the region. Moreover, the presence of a well-established healthcare system and high adoption of minimally invasive surgeries are expected to propel the demand for the cardiovascular & soft tissue repair patch market in North America.
Some of the market players leading the Global Cardiovascular & Soft Tissue Repair Patch Market include Edwards Lifesciences Corporation, BD (Becton Dickinson), W. L. Gore & Associates, Inc., CryoLife, Inc., Baxter International, Inc., Aesculap, Inc. (a B. Braun company), Johnson & Johnson (Medical Devices Business Services, Inc.), Nurami Medical Nanofiber Technology, LeMaitre Vascular, Medtronic, FOC Medical S.A., Admedus, Bone Bank Allografts, Braile Biomédica, Glycar SA Pty Ltd., Inc., CorMatrix, Inc., Medprin Regenerative Medical Technologies Co., Ltd., Terumo Corporation, South America Implants S.A., and Lamed GmbH among others.